News of World Medicine

SEOUL, South Korea — A novel selective T-type calcium channel blocker/inhibitor was effective in improving multiple activities of daily living (ADL) in adult patients with essential tremor (ET), a new phase 3 trial showed.

In Essential3 (E3) Study 1, which included more than 400 participants, those receiving ulixacaltamide 60 mg had significant improvement in all 12 ADL domains assessed at day 56 compared to those who received matching placebo.

Currently, ET is treated with drugs approved for other conditions, such as seizures, headache, and high blood pressure, Farmer noted. “As long as the FDA approves it, we could now have an effective treatment that is just for essential tremor,” she said.

The findings were presented on October 5 at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026.

 

Source: MEDspace